What is the history of Relapsing Polychondritis?

Relapsing polychondritis was first described in 1923 by J. Jaksch-Wartenhorst, who initially termed the condition "polychondropathia." Over the last century, our understanding of relapsing polychondritis has evolved from viewing it as a localized cartilage disorder to recognizing it as a complex, systemic autoimmune disease that can affect multiple organ systems.

Who first identified relapsing polychondritis?

The clinical history of relapsing polychondritis began when Jaksch-Wartenhorst documented a case of systemic cartilage inflammation. Early in the 20th century, the condition was often confused with other rheumatic diseases or even infectious processes. It was not until the mid-20th century, particularly through the work of Pearson and colleagues in 1960, that the systemic nature of relapsing polychondritis—including its tendency to involve the eyes, ears, and respiratory tract—was clearly defined and formally named.

How has our understanding of the disease evolved?

Historically, patients with relapsing polychondritis were often misdiagnosed due to the rarity of the condition and the lack of specific diagnostic blood tests. Modern medical science has shifted the focus toward the immune system’s role in attacking cartilage. We now understand that relapsing polychondritis is a seronegative inflammatory process, meaning it does not typically show the markers found in rheumatoid arthritis. The evolution of imaging and biopsy techniques has significantly improved the time to diagnosis.

What are the historical milestones in treatment?

The management of relapsing polychondritis has progressed through several distinct phases:

• Early 20th Century: Supportive care with limited efficacy in stopping cartilage destruction.


• 1950s–1970s: The introduction of corticosteroids became the standard for managing acute flares.


• Modern Era: The adoption of steroid-sparing agents, including methotrexate, azathioprine, and biologic therapies like infliximab, to manage chronic, systemic involvement.

How has patient advocacy shaped awareness?

As a rare disease, relapsing polychondritis historically left patients feeling isolated. Today, platforms like DiseaseMaps.org connect the 468 community members who have shared their experiences, fostering a global exchange of knowledge that helps patients advocate for earlier diagnostic interventions and improved quality of life.

Next steps

• Consult with a board-certified rheumatologist familiar with systemic autoimmune cartilage disorders.


• Join the DiseaseMaps.org community to connect with other patients and share experiences.


• Request a referral to a center of excellence if you have respiratory or cardiovascular involvement.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• Online Mendelian Inheritance in Man (OMIM)


• PubMed: Historical analysis of Relapsing Polychondritis literature